Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus
NCT ID: NCT01788371
Last Updated: 2013-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
700 participants
INTERVENTIONAL
2009-03-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B
NCT01743079
The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children
NCT02301650
Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus
NCT03695029
"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"
NCT07054359
Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women
NCT02044068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No antiviral arm
provide standard of care to mothers and standard immunoprophylaxis to their infants
No interventions assigned to this group
Lamivudine
lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
Lamivudine
About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
Telbivudine
Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
Telbivudine
About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telbivudine
About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
Lamivudine
About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Icahn School of Medicine at Mount Sinai
OTHER
Hua Zhang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hua Zhang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hua Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing YouAn Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011.6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.